Tag: Genomic Testing

Genomic Testing Cooperative (GTC) to Share 12 Ground-breaking Abstracts at the 2025 American Society of Hematology (ASH) Annual Meeting in Orlando 

December 2, 2025

Lake Forest, CA — December 2, 2025 — Genomic Testing Cooperative (GTC), a leading provider of integrated DNA and RNA next-generation sequencing (NGS) solutions for hematologic tumors and liquid biopsy applications, today announced that its work and data will be presented in 12 abstracts at the ASH 2025 Annual Meeting

Read More »

SNO 25 Posters

November 24, 2025

GTC presented abstracts at the 2025 Annual Meeting of the Society for Neuro-Oncology (SNO).​ GTC participated in the 30th Annual Meeting & Education Day of the Society for Neuro-Oncology (SNO), held at the Hawaii Convention Center in Honolulu, November 19–23, 2025. Our two presented posters are now available for download.

Read More »

67th ASH® Annual Meeting Posters

November 5, 2025

GTC posters at 67th ASH® Annual Meeting (2025) We are delighted to share that GTC collaborated on 12 abstracts at the ASH 2025 Annual Meeting in Orlando, December 6-9. The work represents novel data across machine-learning prediction models, transcriptomic signatures, cell-free RNA (cfRNA) analytics, ethnic-ancestry outcomes, high risk multiple myeloma

Read More »

ASCO 25 Posters

June 3, 2025

GTC presented abstracts at ASCO 2025 GTC’s posters from the 2025 Convention of the American Society of Clinical Oncology are now available for download. Please reach out with any questions. Using cell free DNA (cfDNA) and RNA (cfRNA) in the diagnosis and monitoring of primary and metastatic CNS tumors –

Read More »

cfDNA Chimerism and Somatic Mutation Testing in Early Prediction of Relapse After Allogeneic Stem Cell Transplantationfor Myeloid Malignancies

February 13, 2025

Scott D. Rowley, Maher Albitar, Melissa F. Baker, Alaa Ali, Sukhdeep Kaur, Hyung C. Suh, Andre Goy and Michele L. Donato. Simple Summary: Relapse of disease is a primary cause of treatment failure after allogeneic bone marrow transplantation. Patients may benefit from post-transplant consolidation therapy, but such therapy poses serious

Read More »

ASH 24 Posters

December 10, 2024

GTC presented abstracts at ASH 2024​ GTC’s posters from 2024 Convention of American Society of Hematology are now available to be downloaded. Please reach out with any questions. Establishing a Distinct Cytokine Signature for Multiple Myeloma Using Bone Marrow RNA and Peripheral Blood Cell-Free RNA (cfRNA) ​ Download Poster Establishing

Read More »

Bringing Value to Health Care

June 11, 2024

New Paper in Journal of Clinical Pathways GTC has participated in a new paper titled: Bringing Value to Health Care. Read the paper as it discusses ways to help save money the health care system money and be more efficient.  Bringing Value to Health Care Andrew Pecora, MD Lili Brillstein,

Read More »

ASCO 24 Posters

June 5, 2024

GTC presented abstracts at ASCO 2024 GTC’s posters from 2024 Convention of American Society of Clinical Oncology are now available to be downloaded. Please reach out with any questions. Multiple Alternative Splicing of HER2 transcripts and Exon Skipping with Potential Consequences on Function and Antibody-Based Therapy Download Poster Using Cell-Free

Read More »

Using Targeted Transcriptome and Machine Learning of Pre- and Post-Transplant Bone Marrow Samples to Predict Acute Graft-versus-Host Disease and Overall Survival after Allogeneic Stem Cell Transplantation

April 2, 2024

by Scott D. Rowley 1,2,*,Thomas S. Gunning 3,Michael Pelliccia 3,Alexandra Della Pia 2,Albert Lee 3,James Behrmann 3,Ayrton Bangolo 3,Parul Jandir 3,Hong Zhang 4,Sukhdeep Kaur 2,3,Hyung C. Suh 2,3,Michele Donato 2,3,Maher Albitar 4 andAndrew Ip 2,3 1 Georgetown University School of Medicine, Washington, DC 20007, USA2 John Theurer Cancer Center, Hackensack, NJ 07601, USA3 Hackensack Meridian School of Medicine, Nutley, NJ 07110, USA4 Genomic Testing Cooperative, Irvine,

Read More »